Source desk · A plain-language guide to US care
An average is a clue, not your forecast.
Here is the weight-study result, what it leaves open, and where to check the care details.
The mistaken idea
It is a mistake to expect the same weight loss as the average person in a study.
Where the tirzepatide shortcut fails
A study average describes a group; it cannot promise your own result.
Read who took part, what the comparison was, and how long the study ran.
What the main weight study found
Obesity means excess body fat.
SURMOUNT-1 is the name of a study of people taking the medicine.
SURMOUNT-1 studied adults without diabetes who had obesity, or overweight with a health problem linked to weight.
After 72 weeks, the tirzepatide groups had lost about 15% to 21% of their starting weight on average.
The dummy-shot group lost about 3% over the same period.
A dummy shot looks like the treatment but has no active medicine. It gives the study a comparison.
The drug maker supported the study; participants had regular visits plus help with food and activity.
In SURMOUNT-4, weight returned on average when people switched from tirzepatide to a dummy shot after an initial treatment period.
Ask how progress would be reviewed and what the plan would be if treatment ends.
Read the main weight studyRead the study of continued treatmentCare and licence checks
Use the board's own record when checking a doctor. Match the full name and licence details.
Find the state medical boardRead medical-board guidance on online careRead guidance on prescriptions chosen from a menuAs of 26 September 2026, state rules still apply; medical-board guidance does not replace them.
Medicine checks and urgent help
The FDA is the US Food and Drug Administration.
Find the state's pharmacy licence searchRead the FDA's explanation of compoundingRead the FDA's shortage and copying updatesRead the FDA's concerns about compounded copiesRead the label for Zepbound (tirzepatide)Read the label for Mounjaro (tirzepatide)Read about severe allergic reactionsA label is the product's official medicine information. Ask the person treating you or a pharmacist to explain anything that is unclear.
Prices and Medicare coverage
For the medicine-price range, the source is the drug maker's published Zepbound price and offer terms.
Those terms were recorded on 26 September 2026; the listed offer end date is 31 December 2026.
Check the government's cash-price directoryIts starting-price listing is not the price for every strength or the total cost of care.
The Medicare Bridge is a temporary payment program for certain weight-loss medicines.
Read about the Medicare BridgeRead who can use the Bridge and which products countRead Medicare's patient explanationAsk your plan and the person writing your prescription to check the current terms for your situation.
Questions to ask of the evidence
Does a promising study mean an approved use?
No. As of 26 September 2026, tirzepatide's heart-failure and liver-disease studies had not made those uses FDA-approved.
Approval for a use and a promising study result are separate things.
Does a report of harm prove the drug caused it?
The FDA says reporting a problem is not proof that the medicine caused it.
The FDA also says the reports cannot tell us how common a problem is.
For medicines made to order, the FDA says some problems probably go unreported, so counting reports would miss some problems.
A reported problem may not have been checked by a medical professional, according to the FDA.